ClinicalTrials.gg
CompletedNCT06555822Updated Mar 17, 2025

A Study to Investigate Multiple Ascending Doses and Relative Bioavailability of AZD5004 in Healthy Participants

A Phase 1 interventional study of AZD5004 and Placebo in Healthy Participants, sponsored by AstraZeneca. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-17.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Mar 2025, 1 year 8 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
31
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 52 studies in Obesity by AstraZeneca — 8 open to participants now, 12 under way, 5 of them phase 3. Obesity · AstraZeneca.

Enrollment
41st of 50
31 · median 87
Started
2024
with 3 others
Phase 1
24 of 52
3 open now
Registered
30th of 52
by date

Among the 52 studies in Obesity by AstraZeneca, this one is the 41st largest by enrollment of the 50 interventional ones that give a count, is one of 4 that started in 2024, is one of 24 in phase 1, and was the 30th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

8 of the 52 studies in Obesity by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 52 studies in Obesity by AstraZeneca, or all of them as a file.
02

Study summary

The main purpose of this study is to assess the safety, tolerability, and pharmacokinetic (PK) of AZD5004 administered as multiple oral doses in healthy participants and to compare the relative bioavailability of two oral tablet strengths of AZD5004.

Read the detailed description

This study comprises of 2 parts - Part A and Part B.

Part A is a placebo-controlled study to assess the safety, efficacy, tolerability, and PK of repeated dosing of AZD5004 compared with placebo.

Participants who are eligible according to the inclusion/exclusion criteria will be randomized to receive AZD5004 or matching placebo.

Part A will comprise:

  1. A Screening Period of maximum 28 days.
  2. A Treatment Period of 106 days.
  3. A final Follow-up Visit approximately 14 days after the last study intervention administration.

Part B is a two-way cross-over study to compare the relative bioavailability of 2 oral tablet strengths of Formulation 1 (F1) of AZD5004.

The purpose of this study is to expand product knowledge between the 2 oral tablet strengths on plasma exposure levels to guide Phase 3 drug product development. The participants will be split into 2 groups. Group 1 will be dosed with Treatment 1 of AZD5004 and then dosed with Treatment 2 of AZD5004. Group 2 will be dosed with Treatment 2 of AZD5004 and then dosed with Treatment 1 of AZD5004.

Part B of the study will comprise:

  1. A Screening Period of maximum 28 days.
  2. Two Treatment Periods, each consisting of 7 days.
  3. A final Follow-up Visit approximately 6 days after the last dose of study intervention administration.
03

Conditions studied

  • Healthy Participants

Keywords

  • Obesity
  • Type 2 Diabetes
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must have suitable veins for cannulation or repeated venipuncture.
  • Female(s) of must use adequate (oral contraceptives are not permitted).
  • Have a ≥ 23 kg/m2 and not exceeding 35 kg/m2 inclusive and weigh at least 60 kg.
  • No or off statin treatment for ≥ 4 weeks prior to the study treatment.

Exclusion criteria

Exclusion Criteria:

  • History of any disease or disorder.
  • History of acute pancreatitis, chronic pancreatitis, gallstones, or elevation in serum lipase/pancreatic amylase.
  • History or presence of gastrointestinal, hepatic, or renal disease.
  • Clinically significant hepatic disease, inflammatory bowel disease, gastroparesis, severe disease, or surgery affecting the upper gastrointestinal tract.
  • Any clinically important abnormalities in clinical chemistry, hematology, or urinalysis results.
  • Any clinically important abnormalities in rhythm, blood pressure, heart rate, conduction or morphology of the resting (ECG).
  • Uncontrolled thyroid disease, defined as thyroid-stimulating hormone > 6.0 mIU/L or \< 0.4 mIU/L at Screening.
  • Current smokers or known history of alcohol or drug abuse.
  • History of severe allergy/ or excessive intake of caffeine-containing drinks or food.
  • Use of any prescribed or nonprescribed medication including antacids or analgesics.
  • Participants who are on or are planning to undertake a weight loss program.
  • History of psychosis, major depressive disorder, suicide attempt or suicidal ideation within the past year.
  • Lactating, breastfeeding, or pregnant females or females who intend to become pregnant.
  • Participants who are vegans or have medical dietary restrictions.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
31 participants (actual)

Study arms

  • Experimental
    Part A: Multiple Ascending dose (MAD) (AZD5004)

    Participants will receive repeated dosing of AZD5004 orally.

    Drug: AZD5004

  • Placebo comparator
    Part A: Placebo

    Participants will receive matching Placebo orally.

    Drug: Placebo

  • Experimental
    Part B: Treatment 1 (AZD5004)

    Participants in Group 1 will receive Treatment 1 of AZD5004 and then Treatment 2 of AZD5004. Participants in Group 2 will receive Treatment 2 of AZD5004 and then Treatment 1 of AZD5004.

    Drug: AZD5004

  • Experimental
    Part B: Treatment 2 (AZD5004)

    Participants in Group 1 will receive Treatment 1 of AZD5004 and then Treatment 2 of AZD5004. Participants in Group 2 will receive Treatment 2 of AZD5004 and then Treatment 1 of AZD5004.

    Drug: AZD5004

Interventions

  • Participants will receive oral tablets of AZD5004 in Part A and Part B of the study as per arms they are assigned.

    Also known as: ECC5004

  • DrugPlacebo

    Placebo will be administered as an oral tablet once daily.

06

What researchers measure

Primary outcomes

  1. Part A: Number of participants with adverse events (AEs) and serious adverse events (SAEs)

    To assess the safety and tolerability of AZD5004 following oral multiple ascending doses in healthy participants.

    Time frame: From screening (Day -28) to last follow up visit (Day 120)

  2. Part B: Maximum observed plasma (peak) drug concentration (Cmax) of AZD5004

    To evaluate the Cmax of 2 treatments of AZD5004 in healthy participants.

    Time frame: From Day 1 (Treatment Period 1) to Day 13 (end of Treatment Period 2)

  3. Part B: Area under the concentration-curve from time zero to the last quantifiable concentration (AUClast)

    To evaluate the AUClast of 2 treatments of AZD5004 in healthy participants.

    Time frame: From Day 1 (Treatment Period 1) to Day 13 (end of Treatment Period 2)

  4. Part B: Area under concentration-time curve from time 0 to infinity (AUCinf)

    To evaluate the AUCinf of 2 treatments of AZD5004 in healthy participants.

    Time frame: From Day 1 (Treatment Period 1) to Day 13 (end of Treatment Period 2)

  5. Part B: Time to reach maximum observed concentration (tmax)

    To evaluate the tmax of 2 treatments of AZD5004 in healthy participants.

    Time frame: From Day 1 (Treatment Period 1) to Day 13 (end of Treatment Period 2)

Secondary outcomes

  1. Part A: Maximum observed plasma (peak) drug concentration (Cmax) of AZD5004

    To characterize the Cmax of multiple ascending doses of AZD5004 in healthy participants.

    Time frame: From Day 1 to last follow up visit (Day 120)

  2. Part A: Area under the concentration-curve from time zero to the last quantifiable concentration (AUClast)

    To characterize the AUClast of multiple ascending doses of AZD5004 in healthy participants.

    Time frame: From Day 1 to last follow up visit (Day 120)

  3. Part A: Area under concentration time curve in the dosing interval (AUCtau)

    To characterize the AUCtau of multiple ascending doses of AZD5004 in healthy participants.

    Time frame: From Day 1 to last follow up visit (Day 120)

  4. Part A: Amount of unchanged drug excreted into urine from time t1 to time t2 (Ae[t1-t2])

    To characterize the Ae(t1-t2) of multiple ascending doses of AZD5004 in healthy participants.

    Time frame: From Day 1 to last follow up visit (Day 120)

  5. Part A: Percentage of dose excreted unchanged in urine from time t1 to time t2 (fe[t1-t2])

    To characterize the fe(t1-t2) of multiple ascending doses of AZD5004 in healthy participants.

    Time frame: From Day 1 to last follow up visit (Day 120)

  6. Part A: Renal clearance (CLR)

    To characterize the CLR of multiple ascending doses of AZD5004 in healthy participants.

    Time frame: From Day 1 to last follow up visit (Day 120)

  7. Part A: Percentage change from Baseline in body weight (kg)

    To assess the effects of AZD5004 compared to placebo on body weight change from baseline.

    Time frame: Baseline (Day - 2) to Days 49, 91, and 106

  8. Part A: Absolute change from Baseline in body weight (kg)

    To assess the effects of AZD5004 compared to placebo on body weight change from baseline.

    Time frame: Baseline (Day - 2) to Days 49, 91, and 106

  9. Part A: Percentage change from Baseline in Body Mass Index (BMI) (kg/m^2)

    To assess the effects of AZD5004 compared to placebo on body weight change from baseline.

    Time frame: Baseline (Day - 2) to Days 49, 91, and 106

  10. Part A: Absolute change from Baseline in BMI (kg/m^2)

    To assess the effects of AZD5004 compared to placebo on body weight change from baseline.

    Time frame: Baseline (Day - 2) to Days 49, 91, and 106

  11. Part B: Number of participants with adverse events (AEs) and serious adverse events (SAEs)

    To evaluate the safety and tolerability of 2 treatments of AZD5004 in healthy participants.

    Time frame: From screening (Day -28) to last follow up visit (Day 14)

07

Study locations

1 site
  • Research Site
    Brooklyn, Maryland 21225, United States
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. "Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2024 to primary completion in Mar 2025, 6 months.

Of 335 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 6 months is below that.

Counting every sponsor, half of 440 studies reached it within 11 months; a quarter within 6 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 13, 2024
First posted
Aug 15, 2024
StartActual
Aug 15, 2024
Primary completionActual
Mar 6, 2025
CompletionActual
Mar 6, 2025
Last update
Mar 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06555822
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Aug 15, 2024
Start date
Aug 15, 2024
Primary completion
Mar 6, 2025
Completion
Mar 6, 2025
Last update
Mar 17, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Elecoglipron

Start the discussion